JACKSON LABORATORY - NICHD: R&D: TO PRODUCE, POTENTIALLY ACQUIRE, MAINTAIN, AND DISTRIBUTE MOUSE MODELS FOR CYTOGENETIC RESEARCH, SPECIFICALLY MODELS FOR DOWN SYNDROME (HUMAN TRISOMY FOR CHROMOSOME 21): SEVERABLE
Key Details
Description
NICHD: R&D: TO PRODUCE, POTENTIALLY ACQUIRE, MAINTAIN, AND DISTRIBUTE MOUSE MODELS FOR CYTOGENETIC RESEARCH, SPECIFICALLY MODELS FOR DOWN SYNDROME (HUMAN TRISOMY FOR CHROMOSOME 21): SEVERABLE
Context & Analysis
On Mar 4, 2026, Department of Health and Human Services obligated $649,999 to JACKSON LABORATORY for nichd: r&d: to produce, potentially acquire, maintain, and distribute mouse models for cytogenetic research, specifically models for down syndrome (human trisomy for chromosome 21): severable. The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a cost no fee contract. Competition extent: not competed with 1 offer received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in BAR HARBOR, ME. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541714 — related awards are listed below.
Contractor Information
Related Opportunities
Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
HEALTH AND HUMAN SERVICES, DEPARTMENT OF.OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE.BARDA - ASPR / DAAPPO / BARDA DCMA
BARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003)
HEALTH AND HUMAN SERVICES, DEPARTMENT OF.OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE.BARDA - ASPR / DAAPPO / BARDA DCMA
Similar Awards
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ALLUCENT GOVERNMENT SERVICES (US) LLC
$370.1M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC.
$330.2M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
TECHNICAL RESOURCES INTERNATIONAL, INC.
$317.1M
ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION
PARATEK PHARMACEUTICALS, INC
$265.3M
ASPR-18-04963 -- FUNDING FOR BALOXAVIR MARBOXIL ACTIVITIES FOR BASE PERIOD TASK UNDER THE GENENTECH OTA
GENENTECH INC
$243.7M
Stay Updated
Get notified about new opportunities matching your interests.